MTD
Mettler Toledo International Inc/ Health Care Laboratory Analytical Instruments S&P 500Russell 3000
$1,674.81Close
$37.1BMarket cap
$1,025.53 – $1,718.6152-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Near its high 3% below its 52-week high
Cautions
- Extended 5.0 ATR above its 50-day average
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
up 0.3%
price change
1mo
up 10.8%
price change
12-month return
up 22%
market up 11% ·
its own up 9%
F-score
6 / 9
Mixed
Altman Z
11.57
Low risk
P/E
42.7×
price / earnings
PEG
11.04
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 2.9%
EBIT / enterprise value
Cheaper than
41%
of the market · around average
Revenue growth
up 4%
year on year
EPS growth
up 18%
latest quarter · +12 pts
Sales growth
up 4%
latest quarter · -3 pts
ROE
—
return on equity
Free cash margin
up 21%
$848.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
1.8×
Interest cover
16.3×EBIT / interest
Piotroski tests
- took on more long-term debt
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- short-term liquidity improved
- assets working harder
Trade setup
ATR%
2.4%
$40.73 a day · 2×ATR $1,593.35
RS
78 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.49
50 sessions
Implied move
9.1%
by Nov 20, 2026 · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$23.6M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Shareholders diluted The share count rose 5.7% over the year, from 21m to 22m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 30, 2026
Options
$235,48539.0% IV · activity
Financials
- Gross 59%
- Net 22%
- Free cash 21%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | $3.7B | $3.9B | $3.8B | $3.9B | $4.0B |
| Gross margin | 58% | 58% | 59% | 59% | 60% | 59% |
| Net income | $602.7M | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M |
| Net margin | 20% | 21% | 22% | 21% | 22% | 22% |
| Earnings per share | $24.91 | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 |
| Free cash flow | $632.2M | $801.2M | $737.8M | $860.6M | $864.4M | $848.6M |
| Free cash margin | 20% | 22% | 19% | 23% | 22% | 21% |
| Cash | $94.3M | $98.6M | $96.0M | $69.8M | $59.4M | $66.9M |
| Long-term debt | $1.3B | $1.6B | $1.9B | $1.9B | $1.8B | $2.1B |
| Shareholders' equity | $282.7M | $171.4M | $24.8M | -$149.9M | -$126.9M | -$23.6M |
| Shares outstanding | 23.47m | 22.84m | 22.14m | 21.53m | 20.95m | 22.14m |
Next report
Nov 5, 2026 · after the close
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±9.1%
$1,522 – $1,828 by Nov 20, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±1.6%
last 4: +2.0% · -15.3% · -1.2% · -0.0%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
5.8× the usual move
What options price now
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 39.0% priced · 22.1% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $235,485 calls $83,288 · puts $152,198 · latest session
- 1.83×
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +244 · puts +239 past week
For options traders: ATM IV 39.0% (+2.6% 1w) · 1m ÷ 3m IV 1.25 · 25Δ skew 0.1 pts · Net GEX $8.6M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 31, 2026 | Quarterly ↗ | Jun 30, 2026 | 31d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 6, 2026 | Annual ↗ | Dec 31, 2025 | 37d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 1, 2025 | Quarterly ↗ | Jun 30, 2025 | 32d |
| May 2, 2025 | Quarterly ↗ | Mar 31, 2025 | 32d |
| Feb 7, 2025 | Annual ↗ | Dec 31, 2024 | 38d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Feb 9, 2024 | Annual ↗ | Dec 31, 2023 | 40d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 3, 2026 | Director or officer change · Regulation FD ↗ |
| Jul 30, 2026 | Results ↗ |
| May 13, 2026 | Director or officer change ↗ |
| May 11, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 5, 2026 | Results ↗ |
| Jan 20, 2026 | Director or officer change · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 23, 2025 | Director or officer change ↗ |
| Aug 4, 2025 | Director or officer change · Regulation FD ↗ |
| Aug 1, 2025 | Results ↗ |
| May 12, 2025 | Director or officer change ↗ |